应用ABC转运蛋白抑制剂治疗肿瘤化疗耐药的现状与对策
被引量：1
摘要
在临床中较高的耐药发生率限制了化疗药物的效果,而ABC转运蛋白介导的耐药溢出泵在其中发挥了重要作用。本文综述了近年ABC转运蛋白抑制剂的发展及相关临床试验,分析了试验结果欠佳的潜在原因,并总结了为突破上述瓶颈问题而展开的新型治疗手段。
出处
《现代妇产科进展》
CSCD
北大核心
2015年第4期299-302,共4页
Progress in Obstetrics and Gynecology
基金
上海市卫生系统重要疾病联合攻关项目资助(No:2013ZYJB0202)
参考文献41
-
1Gillet JP, Gottesman MM. Advances in the molecular de- tection of ABC transporters involved in multidrug resist- ance in cancer[ J]. Cur Pharmaceutical Biotechnol,2011, 12(4) :686-692.
-
2Yu M, Ocana A, Tannock IF. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresis- tance:why has it failed to provide clinical benefit? [ J] . Cancer Metastasis Rev,2013,32(1-2) :211-227.
-
3Ueda K. ABC proteins protect the human body and main- tain optimal health [ J ]. Biosci Biotechnol Biochem, 2011, 75(3) :401409.
-
4Keppler D. Muhidrug resistance proteins (MRPs, AB- CCs):Importance for pathophysiology and drug therapy [ J ]. Handb Exp Pharmaco1,2011, (201) :299-323.
-
5Chico I, Kang MH, Bergan R, et al. Phase I study of infu- sional paclitaxel in combination with the P-glyeoprotein antagonist PSC 833 [ J]. J Clin Oncol, 2001,19 ( 3 ) : 832- 842.
-
6Lhomme C, Joly F, Walker JL, et al. Phase III study of val- Spodar (PSC 833) combined with paclitaxel and carbopla- tin compared with paclitaxel and carboplatin alone in pa- tients with stage IV or suboptimally debulked stage III epi- thelial ovarian cancer or primary peritoneal cancer [ J ]. J Clin Oncol,2008,26(16) :2674-2682.
-
7Saeki T, Nomizu T, Toi M, et al. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxo- rubicin, and fluorouracil for patients with advanced or re- current breast cancer [ J ]. J Clin Oncol, 2007,25 ( 4 ) : 411-417.
-
8Gandhi L, Harding MW, Neubauer M, et al. A phase II study of the safety and effieaey of the multidrug resistanee inhibitor VX-710 eombined with doxorubiein and vineris- tine in patients with recurrent small cell lung cancer[ J]. Cancer,2007,109 ( 5 ) : 924-932.
-
9Kuppens IE, Witteveen EO, Jewell RC, et al. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elaeridar ( GF120918 ) and oral topoteean in cancer pa- tients [ J ]. Clin Cancer Res ,2007,13 ( 11 ) :3276-3285.
-
10Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of Pglyeoprotein, does not improve the onteome of older patients with newly diagnosed acute myeloid leu- kemia : A randomized, plaeebo-eontrolled trial of the East- ern Cooperative OncologyGroup 3999 [ J ]. Blood, 2010, 116(20) :40774085.
同被引文献3
-
1成人急性髓系白血病（非急性早幼粒细胞白血病）中国诊疗指南（2011年版）[J].中华血液学杂志,2011,32(11):804-807. 被引量：185
-
2李薇,周明,罗科玲,谭熹,雷平,邹彬宾.急性髓系白血病中乳腺癌耐药蛋白基因表达与临床意义[J].中国现代医学杂志,2016,26(2):29-32. 被引量：4
-
3吴祥猛,盛莉,贾雨霏,李燕.乳腺癌耐药蛋白在药物代谢动力学中的作用[J].药学学报,2016,51(9):1368-1377. 被引量：3
-
1郑树.恶性肿瘤的防治现状与对策[J].科技通报,1992,8(3):129-134.
-
2黄富麟,高长明.江苏省肿瘤防治研究现状与对策[J].中国肿瘤情报,1990(10):1-3.
-
3石景森,孙学军,郑见宝.原发性胆囊癌的临床诊治现状与对策[J].外科理论与实践,2013,18(2):101-103. 被引量：3
-
4程永德,詹迎江.我国肿瘤介入治疗的现状与对策[J].中国肿瘤,2000,9(9):406-407. 被引量：1
-
5郑树.恶性肿瘤的防治现状与对策[J].浙江肿瘤通讯,1991(2):1-5.
-
6潘铁,孙丽华,肖伟.辽宁省肿瘤防治现状与对策探讨[J].中国肿瘤,2002,11(1):19-21.
-
7吴勉华.癌性疼痛的中医药研究现状与对策[J].中国中医药信息杂志,2005,12(5):105-108. 被引量：14
-
8欧阳喜,郝腾飞,朱培谦.胃癌淋巴结微转移的研究进展[J].中国普通外科杂志,2015,24(4):589-592. 被引量：10
-
9尹祥洲,王志军,耿文浩.肝门部胆管癌早期诊断分析[J].中国实用医药,2008,3(7):25-26.
-
10李晔,王知力.乳腺导管内乳头状瘤:剪切波弹性成像评价乳腺病变良恶性误诊的潜在原因[J].中国医学影像学杂志,2015,23(12):896-899. 被引量：22
